France Precision Medicine Market Size & Outlook, 2026-2033
The precision medicine market in France is expected to reach a projected revenue of US$ 8,983.4 million by 2033. A compound annual growth rate of 16.1% is expected of France precision medicine market from 2026 to 2033.
The France precision medicine market generated a revenue of USD 2,746.6 million in 2025 and is expected to reach USD 8,983.4 million by 2033.
The France market is expected to grow at a CAGR of 16.1% from 2026 to 2033.
In terms of segment, therapeutics was the largest revenue generating application in 2025.
Diagnostics is the most lucrative application segment registering the fastest growth during the forecast period.
Precision medicine market data book summary
Market revenue in 2025
USD 2,746.6 million
Market revenue in 2033
USD 8,983.4 million
Growth rate
16.1% (CAGR from 2026 to 2033)
Largest segment
Therapeutics
Fastest growing segment
Diagnostics
Historical data
2021 - 2024
Base year
2025
Forecast period
2026 - 2033
Quantitative units
Revenue in USD million
Market segmentation
Diagnostics, Therapeutics
Key market players worldwide
Roche, Siemens Healthineers AG ADR, Janssen Pharmaceuticals, Illumina Inc, Quest Diagnostics Inc, 23andMe Holding Co Class A, NeoDiagnostix, International Business Machines Corp, Myriad Genetics Inc, Medtronic PLC, GE HealthCare Technologies Inc Common Stock, Abbott Laboratories, Dakota Software, Biogen Inc, Qiagen NV, ImmunityBio Inc Ordinary Shares
Other key industry trends
In terms of revenue, France accounted for 2.4% of the global precision medicine market in 2025.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
In Europe, Germany precision medicine market is projected to lead the regional market in terms of revenue in 2033.
UK is the fastest growing regional market in Europe and is projected to reach USD 15,236.5 million by 2033.
The healthcare system in France relies heavily on government funds and national healthcare insurance. In 2015, a French Plan for Genomic Medicine 2025 was licensed. This plan was further developed and streamlined in 2016 by the French National Alliance for Life Sciences and Health (Aviesan). It was designed to facilitate the integration of genomic medicine in healthcare.
The plan also aims at establishing a genomic medicine industry that penetrates across France, boosting economic growth and innovation. Approximately USD 822 million had been invested in the first 5 years, with more than USD 200 million anticipated to be recovered from the industry. The initiative focuses on positioning France as a leading player in the precision and personalized medicine space by integrating genomic medicine into healthcare.
Furthermore, Human Precision MEDicine (Hu-PreciMED) project was launched by Intersystem & Oncodesign and is aimed at structuring the precision medicine industry in France. It includes over 45 medical and digital companies. Cap Digital and Medicen Paris Region are the prominent players that support advancements in this project.
France precision medicine diagnostics therapeutics market
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Precision Medicine Market Outlook will help companies and investors design strategic landscapes.
Therapeutics was the largest segment with a revenue share of 92.22% in 2025.
Horizon Databook has segmented the France precision medicine market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2021 to 2033.
The healthcare system in France relies heavily on government funds and national healthcare insurance. In 2015, a French Plan for Genomic Medicine 2025 was licensed. This plan was further developed and streamlined in 2016 by the French National Alliance for Life Sciences and Health (Aviesan). It was designed to facilitate the integration of genomic medicine in healthcare.
The plan also aims at establishing a genomic medicine industry that penetrates across France, boosting economic growth and innovation. Approximately USD 822 million had been invested in the first 5 years, with more than USD 200 million anticipated to be recovered from the industry. The initiative focuses on positioning France as a leading player in the precision and personalized medicine space by integrating genomic medicine into healthcare.
Furthermore, Human Precision MEDicine (Hu-PreciMED) project was launched by Intersystem & Oncodesign and is aimed at structuring the precision medicine industry in France. It includes over 45 medical and digital companies. Cap Digital and Medicen Paris Region are the prominent players that support advancements in this project.
France Precision Medicine Market Application Outlook (Revenue, USD Million , 2021-2033)
Diagnostics
Therapeutics
France Precision Medicine Market End Use Outlook (Revenue, USD Million , 2021-2033)
Home Care
Hospitals
Clinical Laboratories
Others
Reasons to subscribe to precision medicine diagnostics therapeutics market databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of precision medicine diagnostics therapeutics market databook
Our clientele includes a mix of precision medicine diagnostics therapeutics market companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the France precision medicine diagnostics therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into France precision medicine diagnostics therapeutics market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
France Precision Medicine Market, 2021-2033 (US$M)